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Abstract
Background: Capillary leak syndrome (CLS) is a rare condition characterized by recurrent episodes of generalized
edema and severe hypotension associated with hypoproteinemia. Interleukin-11 (IL-11) is a promising therapeutic
agent for thrombocytopenia. A direct correlation between IL-11 and CLS has never been reported previously,
particularly in patients with hepatic carcinoma.
Case presentation: We describe two cases of CLS after IL-11 administration in two males with thrombocytopenia.
Case 1 was a 46-year-old man with recurrence of hepatic carcinoma who was treated with IL-11 (3 mg per day).
After four days of therapy, hypotension and hypoproteinemia were detected. The chest X-ray and B ultrasound of
the abdomen showed pleural effusion and ascites. IL-11 was then discontinued, fluid resuscitation was performed,
and fresh frozen plasma and packed red blood cells were transfused into this patient. The patient had recovered
after 19 days of treatment.
Case 2 was a 66-year-old man who had undergone radiofrequency ablation (RFA) for hepatic carcinoma. He was
treated with IL-11 (3 mg per day) for thrombocytopenia. After two days of therapy, this patient complained of
dyspnea with bilateral edema of the hands. Laboratory values showed hypoproteinemia. IL-11 was stopped and
human albumin was transfused at a rate of 10 g per day. On the 4
th day, fluid resuscitation was performed. The
patient had recovered after treatment for two weeks.
Conclusions: The detection of IL-11-induced CLS supports the hypothesis that CLS could be a severe side effect of
IL-11 treatment in some patients. These two case reports also demonstrate that patients with hepatic carcinoma
who experience this rare form of CLS after treatment with IL-11 seem to respond to a therapeutic regimen that
involves hydroxyethyl starch, albumin, and diuretic therapy. Liver cancer patients might be more susceptible to CLS
because of poor liver function and hypersplenia. In addition, bleeding after RFA might be a further inducer of CLS.
Background
C a p i l l a r yl e a ks y n d r o m e( C L S )i sar a r ec l i n i c a ls y n -
drome that was first described in 1960. In the vast
majority of cases, it is characterized by acute episodes of
generalized edema, hemoconcentration, and hypoprotei-
nemia. The cause of CLS is unknown, and the condition
is probably under recognized because of its nonspecific
symptoms and signs and high mortality rate. Up to and
including 1990, 25 cases of CLS had been analyzed in
total worldwide [1]. In 2007, Matsumura et al. reported
that approximately 57 cases had been identified in total,
12 of whom died of the disease during follow-up [2].
However, in the same year, Dhir et al. stated that there
had been 75 additional reports of CLS since the review
published in 1990 [3]. We have found 17 reports in the
last 3 years; four of which occurred in infants and none
in patients with liver cancer. Therefore, the number of
reported cases of this syndrome now totals 117, and has
shown an increasing trend since this syndrome was first
recognized. In contrast to the poor survival noted pre-
viously, the prognosis of this syndrome now seems to be
fair, with a 5-year survival rate of 70%. Further under-
standing of this enigmatic syndrome is needed.
Many drugs are known to induce CLS, including
interleukin-2 (IL-2) [4], gemcitabine [5], doxorubicin [6],
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interferon [8]. Hsiao et al. described the first case of
CLS induced by molecular target medicine in 2010 [9].
Miscellaneous conditions such as carbon monoxide poi-
soning [10], postpartum state [11], and pustular psoria-
sis [12] have been also associated with CLS.
To our knowledge a correlation between CLS and IL-
11 in patients with liver cancer has never been reported.
The identification of IL-11-induced CLS is quite impor-
tant, because it supports the hypothesis that IL-11 is
responsible for the pathogenesis of IL-11-related acute
hypotension. Given that no effective treatment for CLS
has been found so far, CLS can lead to death if the
blood pressure is not increased during the initial capil-
lary leak phase. Usually CLS responds successfully to




th 2008, a 46-year-old man was admitted to
our hospital with hypersplenia after radiofrequency abla-
tion (RFA) for liver cancer. On the day of admission,
the blood pressure of the patient was 122/76 mmHg,
heart rate was 72 beats per minute (bpm), respiratory
rate was 20 per minute, and oral body temperature was
36.9°C. The chest computed tomography (CT) scan was
normal. Laboratory values were as follows: leukocytes
count 3.0 × 10
9/L; hemoglobin 12 g/dL; hematocrit
35.8%; platelet count 48 × 10
9/L; albumin 3.2 g/dL;
aspartate aminotransferase (AST) 82 IU/L (normal 5-35
IU/L); alanine aminotransferase (ALT) 51.1 IU/L (nor-
mal 5-45 IU/L). Therefore, IL-11 was administered sub-
cutaneously at a dose of 3 mg per day because of
thrombocytopenia.
Four days later, the patient felt fullness of the abdo-
men. His oral body temperature was 39.8°C, blood pres-
sure was 102/61 mmHg, and pulse was 118 bpm. The
breath sounds of the lower right lung were weak. Shift-
ing dullness was detected in the abdomen. Laboratory
values were as follows: leukocytes count 4.2 × 10
9/L;
hemoglobin 11.7 g/dL; hematocrit 34%; platelet count
46 × 10
9/L. Piperacillin/Tazobactam was infused at a
dose of 4.5 g q8 h for prophylaxis against infection.
Indomethacin was administered against fever. However,
the hypotension did not improve. At 21:00 on the same
day, the patient complained of dyspnea and fatigue, his
blood pressure was 86/52 mmHg, pulse was 120 bpm,
and temperature was 40.5°C. The X-ray of his chest is
shown in Figure 1. There were moderate amounts of
ascites in the abdomen as shown by B ultrasound
(Figure 2). As a consequence, fluid infusion was admi-
nistered rapidly to this patient. However, the edema
deteriorated dramatically and he developed oliguria, but
pulmonary edema was not observed. The patient was
transferred to the ICU department at 23:00, when his
blood pressure was 76/49 mmHg, and pulse was 122
bpm. Fluid resuscitation and the administration of dopa-
mine were initiated. On ICU day 2, the laboratory values
were as follows: leukocytes count 7.0 × 10
9/L; hemoglo-
bin 7.5 g/dL; hematocrit 21.7%; platelet count 30 × 10
9/
L. Serum albumin had decreased to 1.8 g/dL. Therefore,
packed red blood cells (pRBCs) 4.0 units with fresh fro-
zen plasma (FFP) 400 ml were transfused into this
patient at 02:00 and infusion of hydroxyethyl starch and
albumin was started. On ICU day 3, serum albumin had
increased to 2.3 g/dL. Over the following days, the
hypovolemic shock and pleural effusion subsided gradu-
ally. However, on ICU day 4, edema of feet, the penis
Figure 1 The right diaphragm and costophrenic angle were
obscured. There was moderate right pleural effusion in case 1 after
treatment with IL-11.
Figure 2 Moderate amounts of ascites were detected in case 1
after treatment with IL-11 by color doppler ultrasound: 2.1 cm
in perihepatic region, 0.8 cm in perisplenic region, and 2.8 cm
in the right lower abdomen.
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treated with albumin (10 g per day), spironolactone (40
mg per day), and hydrochlorothiazide (25 mg per day).
The edema was alleviated gradually. After 19 days of
treatment, the patient was discharged. On the day of
discharge, the laboratory values were as follows: leuko-
cytes count 5.2 × 10
9/L; hemoglobin 11.3 g/dL; hemato-
crit 33.3%; platelet count 65 × 10
9/L. Serum albumin
had increased to 3.1 g/dL.
Case 2
On May 24
th 2010, a 66-year-old man was admitted for
primary liver cancer, with hypersplenia. On the day of
admission, the blood pressure of the patient was 134/76
mmHg, heart rate was 75 bpm, respiratory rate was 19
bpm, and oral body temperature was 36.7°C. Laboratory
values were as follows: leukocytes count 5.6 × 10
9/L;
hemoglobin 12.1 g/dL; hematocrit 34.8%; platelet count
63 × 10
9/L; albumin 2.6 g/dL; AST 78 IU/L; and ALT
49 IU/L. After RFA, IL-11 was administered subcuta-
neously at a dose of 3 mg per day because of thrombo-
cytopenia. Two days after the initiation of IL-11, the
patient complained of dyspnea with bilateral edema of
the feet. On physical examination, his temperature was
36.9°C, blood pressure was 93/59 mmHg, and pulse was
92 bpm. Fine rales could be heard by auscultation. Shift-
ing dullness was detected in the abdomen. Edema of the
hands was also observed (Figure 4). Laboratory values
were as follows: leukocytes count 8.9 × 10
9/L; hemoglo-
bin 10.7 g/dL; hematocrit 30.6%; platelet count 51 ×
10
9/L; albumin 1.99 g/dL. Ascites puncture revealed a
few red blood cells in the ascites and the level of albu-
min in the ascites was 1.3 g/dL. IL-11 was stopped and
human albumin was infused at 10 g per day. Somatosta-
tin was administered by intravenous push at a dose of
0.25 mg/hour. Platelets and FFP were also infused. On
the 4
th day after the termination of IL-11, the serum
Figure 3 Bilateral lower extremity edema, scrotum edema and penis edema were observed after treatment with IL-11 in case 1.
Figure 4 After treatment with IL-11, bilateral edema of the
hands were observed in case 2.
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range 0.7-1.3 mg/dL), and fluid resuscitation was per-
formed after consultation with the urology department.
The 24-hour urine volume was 1500-2000 ml after the
use of furosemide. Six days after the termination of IL-
11, the edema of the feet and dyspnea were alleviated.
Two weeks after the termination of IL-11, the patient
was discharged. The laboratory values were as follows:
leukocytes count 4.5 × 10
9/L; hemoglobin 10.6 g/dL;
hematocrit 30.2%; and platelet count 67 × 10
9/L. Serum
albumin had increased to 3.3 g/dL.
Conclusions
IL-11 is a cytokine derived from stromal cells that has
multiple effects on thrombocytopenia induced by che-
motherapy or bone marrow transplantation (BMT). It
was considered to be a safe and well tolerated agent for
the treatment of thrombocytopenia after chemotherapy
by several clinical trials [13-15]. In addition, IL-11 might
be crucial in the acute management of certain types of
hypersplenic thrombocytopenia in hepatic carcinoma
[16]. Therefore, we choose IL-11 to platelet transfusion,
which used to treat thrombocytopenia for preventing
life-threatening bleeding episodes in patients with hepa-
tic carcinoma from radiofrequency ablation. The most
common side effects of IL-11 are arthralgias and myal-
gias, fatigue, nausea, and headache [13]. Mild edema
and minor conjunctival bleeding are also associated with
the administration of IL-11. The most severe side effects
of IL-11 are tachycardia and hypotension, but these sel-
dom occur [14]. To our knowledge, CLS due to the use
of IL-11 has never been reported previously, particularly
in liver cancer patients.
Herein, we describe two cases of liver cancer patients
with anasarca, pleural effusion, and ascites. Clinical and
laboratory findings were consistent with an acute episode
of CLS. Treatment with hydroxyethyl starch, albumin,
and diuretic led to a gradual improvement within 2
weeks. These findings should help to improve the under-
standing and treatment of this potentially deadly severe
side effect of IL-11. Both patients had hypersplenia and
elevated levels of ALT and AST, and it seemed likely that
these findings were due to the side effects of a drug, such
as IL-11, after RFA therapy. The first patient was treated
with antibiotics after RFA for prophylaxis against infec-
tion because he had a high temperature. However, it
became apparent from the subsequent pathogenesis that
the symptoms described above were not due to infection,
because the patient had hypoalbuminemia and the blood
pressure continued to decrease. Some studies have
demonstrated that IL-11 can be used in patients not only
to promote platelet recovery but also to prevent life-
threatening infections [17].
During the state of shock, hemoconcentration was not
observed, but the hematocrit of the patient was
decreased. As a consequence, hemorrhage should have
been considered in this patient. However, in this patient,
the level of hemoglobin and hematocrit increased to
normal without the infusion of platelets and hemostasis.
The patient did have pleural effusion, ascites and edema
in both feet and the scrotum, which were all consistent
with CLS, and thus it is likely that the main cause of
the observed symptoms was CLS.
It was interesting that hemorrhage was also identified
firstly in the second patient. According to some clinical
trials, the proportion of hemorrhagic complications after
RFA is approximately 1.5% [18]. Specific treatments,
such as blood transfusion and drainage, are required in
high-risk patients. However, in the second patient, the
level of albumin in the ascites was higher than normal.
Hypoalbuminemia and lower blood pressure occurred
soon after the initiation of IL-11 and serum Cr was also
increased because of hypovolemia. Therefore, the patient
was not just a simple hemorrhage, and CLS needed to
be considered. Finally, the symptoms of this patient
were alleviated by combined treatment with hemostasis
and fluid resuscitation, which confirmed that CLS was
the main cause of the observed symptoms and hemor-
rhage might be a secondary reason. There is also the
possibility that CLS can be induced by hemorrhage in
patients with liver cancer.
The pathogenesis of CLS caused by IL-11 was not elu-
cidated. Some studies have found that vascular endothe-
lial growth factor (VEGF) is associated with CLS [19,20].
Furthermore, studies in animal models have shown that
the synthesis of nitric oxide (NO) is strongly induced
during CLS after cytokine treatment [21]. Another study
found that isoforms of NO synthase (NOS), such as
endothelial NOS, might play a major role in CLS [22].
Liver pathologies have a negative influence on numerous
conditions, including those that affect the endothelial
system [23]. In this report, both patients had chronic
bleeding after RFA, which indicated that injury of the
liver and hypersplenia might be a precipitating factor for
CLS.
Further studies are necessary with the objective of col-
lecting sufficient patients with CLS to observe the nat-
ural history of the disease and evaluate the efficacy of
empiric treatments. These two cases should help to
improve the understanding and treatment of the poten-
tially deadly CLS that is related to IL-11 and has been
recognized in this study.
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